On March 15, 2023 Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported two upcoming poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meeting 2023 (April 14-19) in Orlando, Florida (Press release, Hummingbird Bioscience, MAR 15, 2023, View Source [SID1234628849]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company will present a poster describing the efficacy of HMBD-001, a clinical-stage anti-HER3 mAb currently in Phase 1a clinical trial (NCT05057013), across multiple preclinical models of squamous cell carcinomas and a poster demonstrating the efficacy and tolerability of HMBD-501, a next generation HER3-targeting antibody-drug conjugate (ADC), in preclinical solid tumor models.
The poster for HMBD-001 highlights that inhibition of HER3 has broad applicability in squamous cell carcinomas and this anti-tumor activity can be enhanced with concurrent inhibition of EGFR, with significant potential to improve patient outcomes. Robust tumor growth inhibition in various preclinical squamous cancer models, including lung, esophageal and head and neck, is observed with HMBD-001 when used as monotherapy and in combination with cetuximab. The HMBD-501 poster discusses the rational design of the HER3 ADC, its potentially best-in-class safety and tolerability profiles, and superior inhibition of tumor growth compared to other HER3 ADCs, across a range of preclinical cancer models.
"We are excited to be on the cusp of the new horizon of therapies for HER3-expressing cancers. At AACR (Free AACR Whitepaper), we will have the first publication of preclinical results for our potentially best-in-class HER3 ADC," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. "The potent anti-tumor activity we see from our clinical-stage HMBD-001 program is exciting and represents a broad treatment opportunity due to conserved sensitivity to HER3 and EGFR inhibition across multiple squamous carcinomas. We look forward to discussing the promising data for our novel HER3-targeting therapeutics with the oncology research community at AACR (Free AACR Whitepaper)."
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies
Session Date and Time: Monday Apr 17, 2023 1:30 PM – 5:00 PM ET
Location: Poster Section 13
HMBD-001 Presentation
Title: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected preclinical models of squamous cell carcinomas
Poster Board Number: 27
Published Abstract Number: 2659
HMBD-501 Presentation
Title: HMBD-501 – a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in preclinical solid tumor models
Poster Board Number: 28
Published Abstract Number: 2660